Kailera Therapeutics to Participate in September Investor Conferences
News related to:Kailera Therapeutics Inc · 1 min read
WALTHAM, Mass., Sept. 16, 2026 /CourierPR/ -- Kailera Therapeutics, a clinical-stage biotechnology firm focused on obesity care, will participate in two upcoming investor conferences in September 2026. The company aims to showcase its pipeline of obesity management medications, including its lead product candidate, ribupatide injection (KAI-9531).
On Wednesday, September 23, 2026, Jamie Coleman, Chief Commercial Officer of Kailera, will deliver a fireside chat at the Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum. This event is designed to bring together key players in the healthcare industry to discuss the latest trends and innovations.
Following this, Kailera will present at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026. The company's CEO, Ron Renaud, Chief Financial Officer, Doug Pagán, and Chief Medical Officer, Scott Wasserman, will participate in a fireside chat. These conferences will provide Kailera with a platform to engage with investors and stakeholders, highlighting the potential of its product candidates.
Kailera's portfolio includes four clinical-stage product candidates, all leveraging multiple GLP-1-based mechanisms of action and routes of administration. The company's lead product, ribupatide injection, is currently in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is also developing a once-daily oral formulation of ribupatide with the goal of providing an oral option that could offer compelling weight loss and highly differentiated tolerability.
Additionally, the company is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. These efforts are part of Kailera's broader vision to deliver category-leading obesity management medications that can help people restore their health and transform their lives.
Kailera's participation in these investor conferences underscores its commitment to expanding its presence in the obesity care market. The company's focus on innovation and its diverse pipeline of product candidates positions it as a leader in the field.